The FDA sets a PDUFA date of October 19.
Thursday, June 20, 2019
Alexion application for Ultomiris gets priority review
The FDA accepts for priority review Alexion’s (NASDAQ:ALXN) supplemental Biologics License Application for Ultomiris (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.